Lipaglyn 4mg Tablet is a composition of Saroglitazar, which is used to treat Noncirrhotic Non-Alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease (NAFLD) with comorbidities (like obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome), and high cholesterol in diabetes (diabetic dyslipidemia).
Lipaglyn 4mg Tablet is a prescription-required drug. It has side effects, such as flatulence, indigestion, abdominal distension, and weakness. Before taking any medication, follow the directions on the label or consult a doctor about the frequency.
Lipaglyn Tablet is taken orally or as required, do not misuse or overdose on these products. It is to be consumed with or without food. Consult a doctor about the recommended dosage and frequency for pregnant women & breastfeeding mothers.
Statins are the first line of treatment for dyslipidaemia. It is mainly indicated when the patient does not respond to statin therapy. Saroglitazar is the world’s first drug for treating diabetic dyslipidaemia or hypertriglyceridaemia in diabetes type II patients who do not respond to statins alone.
Lipaglyn Tablet is a peroxisome proliferator-activated receptor alpha and gamma agonist( PPAR alpha and gamma agonist). The PPAR agonist is a nuclear protein receptor responsible for regulating genes to control lipid metabolism, glucose level maintenance and inflammatory processes.
The significance of Lipaglyn Tablet is due to its treatment for dyslipidaemia which is a significant risk factor for cardiovascular disease, i.e. myocardial infarction/heart attack around the globe.